Adults with severe or moderately severe haemophilia B receiving etranacogene dezaparvovec in the HOPE-B phase 3 trial experience a stable increase in mean Factor IX activity levels and durable haemostatic protection after 24 months’ follow-up
Autor: | W S Pipe, WG F Leebeek, M Recht, S N Key, S Lattimore, G Castaman, M Coppens, D Cooper, R Gut, S Slawka, S Verweij, R Dolmetsch, Y Li, PE Monahan, W Miesbach |
---|---|
Rok vydání: | 2023 |
Zdroj: | GTH Congress 2023 – 67th Annual Meeting of the Society of Thrombosis and Haemostasis Research – The patient as a benchmark. |
ISSN: | 2567-5761 |
Databáze: | OpenAIRE |
Externí odkaz: |